Lymphangiogenesis Is Induced by Mycobacterial Granulomas via Vascular Endothelial Growth Factor Receptor-3 and Supports Systemic T-Cell Responses against Mycobacterial Antigen  by Harding, Jeffrey et al.
The American Journal of Pathology, Vol. 185, No. 2, February 2015IMMUNOPATHOLOGY AND INFECTIOUS DISEASES
ajp.amjpathol.orgLymphangiogenesis Is Induced by Mycobacterial
Granulomas via Vascular Endothelial Growth
Factor Receptor-3 and Supports Systemic T-Cell
Responses against Mycobacterial Antigen
Jeffrey Harding,*y Anna Ritter,* Aditya Rayasam,z Zsuzsanna Fabry,*y and Matyas Sandor*yFrom the Department of Pathology and Laboratory Medicine,* School of Medicine and Public Health, the Cellular and Molecular Pathology Training




Matyas Sandor, Ph.D., 5468
MSC, 1300 University Ave.,
Madison, WI 53705. E-mail:
msandor@wisc.edu.opyright ª 2015 American Society for Inve
ublished by Elsevier Inc. All rights reserved
ttp://dx.doi.org/10.1016/j.ajpath.2014.09.020Granulomatous inﬂammation is characteristic of many autoimmune and infectious diseases. The
lymphatic drainage of these inﬂammatory sites remains poorly understood, despite an expanding
understanding of lymphatic role in inﬂammation and disease. Here, we show that the lymph vessel
growth factor Vegf-c is up-regulated in Bacillus Calmette-Guerine and Mycobacterium tuberculosise
induced granulomas, and that infection results in lymph vessel sprouting and increased lymphatic area
in granulomatous tissue. The observed lymphangiogenesis during infection was reduced by inhibition of
vascular endothelial growth factor receptor 3. By using a model of chronic granulomatous infection, we
also show that lymphatic remodeling of tissue persists despite resolution of acute infection and a 10- to
100-fold reduction in the number of bacteria and tissue-inﬁltrating leukocytes. Inhibition of vascular
endothelial growth factor receptor 3 decreased the growth of new vessels, but also reduced the pro-
liferation of antigen-speciﬁc T cells. Together, our data show that granulomaeup-regulated factors
increase granuloma access to secondary lymph organs by lymphangiogenesis, and that this process
facilitates the generation of systemic T-cell responses to granuloma-contained antigens. (Am J Pathol
2015, 185: 432e445; http://dx.doi.org/10.1016/j.ajpath.2014.09.020)Supported by NIH grant R01-A4048087 (M.S.).
Disclosures: None declared.The lymphatic system is made of a network of tissue-resident
lymphatic endothelial vessels that drain extracellular ﬂuid to
the lymph nodes and back into blood circulation, a process that
is critical in maintaining body ﬂuid balance. Lymphatics also
play a critical role in transporting dendritic cells (DCs) of the
immune system, which may contain bacterial, viral, or fungal
peptides, to T- and B-cell areas in the lymph nodes. Afferent
lymph vessels express high levels of chemokines CCL19/21,
which bind to CCR7 on activated DCs and induce their
migration across lymphatic endothelial cells toward lymph
nodes.1e3 Soluble antigen alone can also ﬂow through the
lymph to the lymph nodes, where it can be acquired by lymph
nodeeresident DCs and presented to T and B cells.4,5 Through
these processes, adaptive immunity and clonal expansion of
lymphocytes are initiated during infection.
Although the role and requirement of lymphatics during
steady-state conditions are well studied, the mechanismsstigative Pathology.
.and consequences of lymphangiogenesis during inﬂammation
are far less so by comparison. Lymphangiogenesis is induced
during neonatal development, as well as postdevelopment
(inﬂammation, infection, and tumor growth) by vascular
endothelial growth factor (VEGF)-C and VEGF-D binding to
vessel-expressed VEGF receptor 3 (VEGFR3).6e9 CD11bþ
monocytes have been identiﬁed as an important initiators of
lymphangiogenesis because they produce VEGF-C and
VEGF-D after proinﬂammatory stimuli10e12 and can inte-
grate into pre-existing lymph vessels and transdifferentiate
into lymphatic endothelial-like cells.13 Recent evidence
shows an unappreciated role for lymphatics and lym-
phangiogenesis beyond transportation of antigen-presenting
cells and peptides to the lymph nodes. These functions
Mycobacteria and Lymphangiogenesisinclude direct modulation of DC and T-cell activation or
tolerance,14e17 the presentation of antigens,18,19 and egress of
T cells from lymph nodes.20,21 The growing appreciation of
diversity in lymphatic function ensures the importance of
understanding lymphangiogenesis during infection and
inﬂammation.
Granulomatous immune responses are associated with
many infectious and autoimmune diseases. The granuloma
itself is a macrophage-dominated collection of leukocytes that
forms with deﬁned spatial and organizational arrangement,
and these sites are important in the protection and pathology
during granulomatous diseases.22e25 During infectious dis-
ease, granulomas contain the immune response-inducing an-
tigens, and so engagement between the peripheral immune
organs and these antigens is required. Lymphatic vessels are
important because they are routes that soluble and DC-carried
antigens use to reach the lymph nodes from granulomatous
tissue. The relationship between the granulomas and lymphoid
vessels, especially in the context of lymphangiogenesis, is not
yet understood. Here, we used two different mycobacterial
models of granulomatous inﬂammation to investigate this
relationship. This ﬁrst involves high-dose infection with the
Bacillus Calmette-Guerin (BCG) strain of mycobacterium,
which induces acute granulomatous inﬂammation in the liver 3
weeks after infection. Resolution of inﬂammation after 3
weeks results in reduced, but persistent, BCG-containing
granulomas in the chronic stages of infection. Granulo-
matous inﬂammation of the liver is a characteristic
pathology of diseases including histoplasmosis26e28 and
schistosomiasis,29e31 and many tuberculosis patients also
have tubercle granulomas in their livers.32e34 We also used
a mouse model involving aerosol infection in the lung with
Mycobacterium tuberculosis (MTB). This model is distinct
from systemic BCG infection because acute granulomatous
inﬂammation does not resolve, and mice eventually suc-
cumb to disease resulting from increasing granuloma and
bacterial burden. Understanding the relationship between
granulomatous inﬂammation and lymphangiogenesis will
undoubtedly involve an understanding of the infectious
context given that granulomas can occur in different
organs and the fact that lymphatic form and function are
adapted to the anatomy of the tissue.
Here, using both models, we show that granulomatous
inﬂammation induces lymphangiogenesis and that the
biology of this process has a regulatory role in the prolif-
eration of mycobacterial-speciﬁc T cells.
Materials and Methods
Mice and Ethics Statement
Wild-type C57BL/6 mice were purchased from the Jackson
Laboratory (Bar Harbor, ME). Mice were housed and bred
in microisolator cages in pathogen-free facilities at the
University of Wisconsin Animal Care Unit (Madison, WI).
All experimental procedures were performed in accordanceThe American Journal of Pathology - ajp.amjpathol.orgwith the guidelines of and all animal protocols were
approved by the University of Wisconsin Institutional An-
imal Care and Use Committee.
BCG and MTB Infection
DsRed BCG was provided by Dr. Lalita Ramakrishnan
(University of Washington, Seattle, WA). BCG was grown
at 37C in Middlebrook 7H9 medium (VWR International,
Radnor, PA) supplemented with 10% oleic acid-albumin-
dextrose-catalase and 0.05% Tween (Fisher Scientiﬁc,
Waltham, MA) and frozen at 80C. Before infection,
frozen stocks were thawed and brieﬂy sonicated. To induce
acute BCG liver infection, mice were i.p. injected with
1  107 colony-forming units (CFU) BCG in 100 mL of
phosphate-buffered saline (PBS). MTB strain H37Rv
(ATCC, Manassas, VA), was transfected with the tdTomato
plasmid, and grown at 37C in Middlebrook 7H9 medium
supplemented with 10% oleic acid-albumin-dextrose-
catalase and 0.05% Tween 80. Live tdTomato H37Rv cul-
ture was taken during mid-logarithmic phase and loaded
directly into an Inhalation Exposure System (Glas-Col,
Terre Haute, IN). Mice were infected with approximately
500 to 1000 CFU aerosolized bacilli using a pre-
programmed nebulization protocol. Growth of MTB,
infection, and collection of tissue was done in a BSL3
facility under approved biosafety guidelines.
CFU
For BCG-infected animals, 300 to 400 mg of liver from the
medium lobe was homogenized in 2 mL of PBS using a tissue
homogenizer, and then diluted 1000-fold. Homogenates were
plated onto Middlebrook 7H10 agar medium (BD Bio-
sciences, San Jose, CA) supplemented with 10% oleic acid-
albumin-dextrose-catalase (Fisher Scientiﬁc, Waltham, MA)
and 0.5% glycerol. Plates were incubated at 37C for 3 weeks
and then the number of colonies counted.
Immunohistochemistry
The entire left lung from MTB-infected mice was ﬁxed in
10% formalin, embedded in parafﬁn, and 35 mm (liver) or
60 mm (lung) sections were cut and mounted. Images of
H&E-stained sections were taken with an Olympus B 40
microscope (Leeds Precision Instruments, Minneapolis,
MN). Separately, sections from the left, median, and right
lobes of the liver, as well as the inferior lobe of the lungs,
were ﬁxed in a 4% paraformaldehyde in PBS solution, with
25% sucrose, for 24 hours and frozen in OCT (Tissue-Tek
Sakura, Torrance, CA). Sections (40 mm thick) were cut and
mounted onto slides, ﬁxed in acetone for 10 minutes, and
washed with PBS. Sections were stained with CD11b (M1/
70; BD Biosciences, San Jose, CA) and lymphatic vessel
endothelial hyaluronan receptor (LYVE-1; clone ALY7;
BioLegend, San Diego, CA) antibodies for 3 hours, washed,433
Figure 1 Lymphangiogenesis during acute Bacillus Calmette-Guerin
(BCG)-induced infection by CD11bþ granulomatous inﬂammation. A:
Micrographs of liver sections (35 mm thick) from uninfected and BCG-
infected mice shows the extent of granulomatous inﬂammation and
CD11bþ cell recruitment into infected tissue. B: LYVE-1 (a lymphatic marker)
staining shows a representative area with increased lymphatic endothelium
in an area with proximity to a granulomatous CD11bþ cell inﬂammation.
White arrowheads identify the wall of the lymphoid vessel, and orange
arrowheads show the lumen. White dashed lines in the far right panels
outline CD11bþ granuloma. C: Flow cytometry plots of granuloma-isolated
cells from the liver of BCG-infected mice stained with CD11b, CD11c, and CD4
antibodies. Plots highlight the dominant CD11bþ granuloma population.
Original magniﬁcation: 40 (A); 200 (B, main image); 400 (right
panels of area outlined in white dashed box, B).
Harding et aland mounted with ProLong Gold Antifade with DAPI
(Invitrogen; Life Technologies, Carlsbad, CA). Images were
obtained with an Olympus BX41 Fluorescent microscope
(Leeds Precision Instruments). To quantitate liver granu-
loma burden, the total number of granulomas was counted
from two 40 ﬁelds from the left, median, and right liver
lobes. A single ﬁeld at 40 magniﬁcation of infected liver
ﬁeld contained 200 to 400 granulomas 21 days after i.p.
injection with 1  107 CFU. The number of granulomas was
normalized by the total area of tissue counted. The total
LYVE-1þ area in the liver was measured in six to eight 40
magniﬁcation ﬁelds in tissue from the median left, median,
and right lobes of each mouse. The total LYVE-1þ area in
MTB-infected lung was measured in 40 magniﬁcation of
the entire left lung. The area was quantiﬁed using ImageJ
software version 1.48 (NIH, Bethesda, MD) by outlining all
pixels containing or enclosed by LYVE-1þ signal and
normalizing the value to the total area of tissue measured.
Cell Isolation and Flow Cytometry
Isolation of cells from the spleen and liver-draining lymph
nodes of BCG-infected mice was performed by manual
homogenization of tissue with glass slides. The anatomic
location of the liver lymph nodes has been previously
described.35 Cells were treated with red blood cell lysis
buffer and then washed in Hanks’ balanced salt solution.
Isolation of liver granuloma cells was performed as pre-
viously described.36 Brieﬂy, infected livers from BCG-
infected animals were homogenized in a tissue blender,
and granulomas were separated from hepatic cells based on
density. Isolates were then washed twice in RPMI and
digested with 5 mg/mL type I collagenase (Sigma-Aldrich,
St. Louis, MO) at 37C for 40 minutes while shaking. After
digestion, tissue homogenate was pipetted and ﬁltered
through a 70-mm nylon cell strainer (BD Biosciences) to
remove excess collagen. Liver granuloma isolates were
then treated with red blood cell lysis buffer and washed
twice with RPMI. To isolate lung leukocytes from MTB-
infected mice, animals were perfused, and the superior,
middle, and postcaval lung lobes were removed and
homogenized in gentleMACS dissociator C-tubes using
the gentleMACS dissociator (Miltenyi Biotec, San Diego,
CA). C-tubes contained 3 mL of PBS with 1 mg/mL type I
collagenase and 28 U/mL DNase. After homogenization,
C-tubes were incubated at 37C for 30 minutes while
shaking. After incubation, leukocytes were isolated via
Percoll separation and washed twice with Hanks’ balanced
salt solution. To isolate leukocytes from the lung-draining
lymph nodes or spleen of MTB-infected animals, tissue
was manually homogenized through a 70-mm nylon cell
strainer and then washed twice with Hanks’ balanced salt
solution. Cell isolates from liver, spleen, lung, and lymph
nodes were then washed with ﬂuorescence-activated cell
sorting staining buffer (1% bovine serum albumin in PBS)
and incubated with ﬂuorochrome-labeled antibodies for 30434minutes. Antibodies against CD4 (RM4-5) and CD11b
(M1/70) were purchased from BD Biosciences. Data from
stained cell isolates was collected on an LSRII (BD Bio-
sciences) and analyzed with FlowJo v. 8.7 (TreeStar,
Ashland, OR).
Vegf-c ELISA
Leukocytes (1  106) from spleen, lung, or liver of BCG-
or MTB-infected mice were incubated for 24 hours in 200
mL of cRPMI (Hanks’ balanced salt solution þ 10% fetal
bovine serum). Vegf-c concentration from supernatants
was measured using a rat Vegf-c enzyme-linked immu-
nosorbent assay (ELISA; Affymetrix; eBioscience, Sanajp.amjpathol.org - The American Journal of Pathology
Figure 2 Characterization of inﬂammation around LYVE-1þ vessels dur-
ing Bacillus Calmette-Guerin (BCG) infection. A: Confocal microscopy of liver
sections (60 mm thick) from CD11c-eYFPeexpressing mice during acute BCG
infection. Areas with granulomatous inﬂammation and representative
lymphatic vessel are shown. Dendritic cell reporter CD11c-eYFP mice received
DsRed-expressing P25 T cells that are speciﬁc for mycobacterial antigen
(orange arrowheads) 1 week before harvest at 21 days postinfection.
Yellow arrowheads show BCG bacilli. Right panels show enlarged area
outlined by white dashed lines in left panels. Areas selected for
enlargement show dendritic cells, BCG bacilli, mycobacterial-speciﬁc T
cells, and BCG in a representative granuloma. B: Colocalization of LYVE-1 and
ICAM-1 (white arrowheads) was detected on lymphatic endothelium in the
liver of BCG-infected mice, but not uninfected controls.
Mycobacteria and LymphangiogenesisDiego, CA). Rat and mouse Vegf-c share almost 100%
sequence homology.
Vegfr3 Blocking
BCG-infected mice were treated with 10 mg/kg/day of
MAZ51 (EMD Millipore, Billerica, MA) in 50 mL of
dimethyl sulfoxide for 7 days before harvest at 21 days
postinfection. MTB-infected mice were treated with 10 mg/
kg/day MAZ51 in 50 mL of dimethyl sulfoxide for 10 days
before harvest at 35 days postinfection. Control animals
were treated with 50 mL of dimethyl sulfoxide/day.
Adoptive Transfer of P25 T Cells
Cells were collected from the spleen and lymph nodes
of P25 DsRed transgenic mice and labeled with carboxy-
ﬂuorescein succinimidyl ester (CFSE) as previously
described37 (ﬁnal concentration of CFSE at 1 mmol/L;
Molecular Probes; Life Technologies). CFSE-labeled trans-
genic T cells (1  106) were then transferred intravenously
into BCG- or MTB-infected mice by retro-orbital injection.
Statistical Analysis
Results are expressed as means  SEM. Signiﬁcance was
determined using the 2-tailed t-test or one-way analysis of
variance. P < 0.05 was considered signiﬁcant.
Results
Lymphangiogenesis during Mycobacterial Infection in
Proximity to Granulomatous Inﬂammation
Wild-type C57BL/6 mice were i.p. infected with a high dose
of BCG, the vaccine strain derived from M. bovis, which
resulted in extensive leukocyte recruitment and granuloma
formation in the liver 3 weeks later (Figure 1, A and B).
BCG-induced liver granulomas were dominated by CD11bþ
cells (Figure 1, AeC), but also contained a smaller popu-
lation of CD11cþ and CD4þ cells (Figure 1C), in addition to
B cells, natural killer cells, and ﬁbroblasts.24 We stained
tissue sections from uninfected and BCG-infected mice with
antibodies against LYVE-1, a well-characterized lymphatic
marker,12,38e41 and CD11b to better understand the rela-
tionship between lymphatics and granulomatous inﬂamma-
tion (Figure 1B). In the liver, lymphatic vessels are present
under noninﬂammatory conditions, and are associated with
portal triads, which are loosely connected structures con-
taining a hepatic portal vein, hepatic artery, and bile ducts.
I.P. infection with BCG resulted in a subset of granulomas
that form directly adjacent to or in proximity with portal
triads and the connecting lymphatic endothelium. BCG
infection resulted in a dramatic increase in the area of
LYVE-1þ surface compared to uninfected controls
(Figure 1B). In BCG-infected mice, every identiﬁedThe American Journal of Pathology - ajp.amjpathol.orglymphatic vessel was surrounded by or in proximity to
CD11bþ granulomatous inﬂammation. Both the endothelium
and lumen (Figure 1B) of many vessels could be observed
given that the tissue sections were 35 mm thick. Our data
suggest that the typical lumen of lymphatic vessel adjacent to435
Figure 3 Continued lymphangiogenesis in the liver despite resolu-
tion of bacillus Calmette-Guerin (BCG) infection. A: Proportion of liver
enclosed by LYVE-1þ staining, as well as total number of LYVE-1þ areas,
in liver sections (35 mm thick) from uninfected and BCG-infected mice.
The proportion and number of detected LYVE-1þ areas were calculated
based on measurements from three to ﬁve 40 magniﬁcation ﬁelds
(among sections taken from the right, median, and left liver lobes) for
each mouse. B: Micrograph of a representative area of lymphatic
endothelium (LYVE-1, indicated by white arrows) in uninfected and
BCG-infected mice. C and D: Number of liver granulomas (C) and CFU in
uninfected and BCG-infected mice (D). n Z 6 to 8 mice per time point
(A, C, and D).
Harding et algranulomatous inﬂammation is one to three cell widths wide,
or 10 to 30 mm. This is ﬁtting with observations that
lymphatic vessels have to be wide enough to facilitate cell
emigration out of infected tissue. Additionally, we conﬁrmed
the speciﬁcity of LYVE-1 as a marker of lymphatic cells by
staining with other and recently identiﬁed lymphatic markers
such as CD90.2 (data not shown).42,43
To show that resident mycobacterial-speciﬁc T cells,
DCs, and BCG are in proximity to lymphatic vessels, we
infected CD11c-eYFP mice. CD11c was expressed on
liver-resident DCs, to a lesser extent on Kupffer cells, and
on inﬂammatory DCs. During mycobacterial infection,
the overwhelming majority of CD11cþ cells in infected
tissue were granuloma-resident inﬂammatory DCs
(Figure 1A).44,45 CD11cþ cells were recruited to the granu-
loma alongside CD11bþ and other cell types (Figure 1C). One
week before harvest, infected CD11c-eYFP mice were
intravenously given DsRed-expressing, mycobacterial-
speciﬁc P25 T cells that recognize a peptide of
the mycobacterial-secreted 85b antigen. As expected,
confocal microscopy of tissue cuts showed that granulo-
matous inﬂammation around lymphatic vessels contained
CD11cþ cells, P25 T cells and BCG (Figure 2A) in
addition to CD11bþ cells. Lymphatic endothelium, like
vascular endothelium, up-regulates adhesion molecules
such as intercellular adhesion molecule-1 (ICAM-1) and
vascular cell adhesion molecule-1 during inﬂammation,46
as well as other chemokines47 and chemokine scavenger
receptors.48 These molecules contribute to the regulation
of leukocyte adhesion, transmigration, and activation
during inﬂammation and especially immune cell egress
from the tissue. LYVE-1þ cells found in BCG-infected,
but not uninfected, liver tissue colocalized with
ICAM-1, indicating their change in phenotype under
inﬂammatory conditions (Figure 2B). Taken together,
these data show that BCG-containing granulomas con-
sisting of CD11bþ and CD11cþ inﬂammatory cells can
induce lymphangiogenesis and a phenotypic change in
lymphatic vessels.
Lymphangiogenesis Continues despite Resolution of
Acute BCG Infection in the Liver
In mice, resolution of acute inﬂammation after BCG infection
occurs as a result of T-cellemediated, antimicrobial immunity
in the phagosome of CD11bþ cells. Despite this response, a
few BCG bacilli are able to persist indeﬁnitely in the granu-
loma (chronic infection).49 We quantiﬁed the extent of lym-
phangiogenesis during BCG infection and correlated it with
both the acute and chronic states of infection. The kinetics and
molecular regulation of lymphangiogenesis has been charac-
terized primarily with acute inﬂammatory models, but less so
with chronic ones. Quantiﬁcation was performed by
measuring the proportion of total area (measured in pixels)
enclosed by LYVE-1þ staining in 35 mm thick liver tissue
sections of uninfected and BCG-infected mice. For each436 ajp.amjpathol.org - The American Journal of Pathology
Figure 4 Vegfr3 regulates lymphangiogenesis during mycobacterial infection. A: Vegf-c concentration from cell culture supernatants of isolated granuloma
and splenic leukocytes (1  106 cells cultured for 24 hours). Leukocytes from Bacillus Calmette-Guerin (BCG)-infected mice were isolated 3 weeks after i.p.
infection (acute). Vegf-c from splenic leukocytes of uninfected mice is below the detection limit of the ELISA. B and C: Mice were treated with 10 mg/kg/day
of MAZ51 (VEGFR3 blocker) after BCG infection for 7 days before harvest. B: Total normalized area of LYVE-1þ staining in MAZ51- and vehicle-treated mice. C:
Representative area of lymphatics shows reduced surface area of LYVE-1þ endothelium in MAZ51-treated mice compared to vehicle-treated controls. D:
Frequency of CD11bþ cells among entire granuloma population in MAZ51-treated and vehicle-treated groups. Representative ﬂow plots from each group are
shown. E: Representative granulomas from treated and untreated groups. F: Total number of cells and CD11bþ cells among treated and untreated groups. G:
Total granuloma number between treated and untreated groups. One-way analysis of variance with Tukey’s post hoc test (B) and t-test (A, D, F, and G) were
used to determine statistical signiﬁcance. Data are expressed as means  SEM (A, B, D, F, and G). *P < 0.05, **P < 0.01 (A and B).
Mycobacteria and Lymphangiogenesismouse, the LYVE-1þ area was measured in six to eight 40
magniﬁcation ﬁelds taken from the left, median, and right liver
lobes. By 3 weeks postinfection (acute infection), there was a
fourfold increase in the total area of LYVE-1þ staining
(Figure 3, A and B), and a twofold increase in the indentiﬁed
number of LYVE-1þ areas in a 35 mm thick tissue cut
(Figure 3, A and B). The increase in LYVE-1þ staining
therefore results from an increase in the number of lymph
vessels and average lymph vessel size. Surprisingly, lym-
phangiogenesis continued up to 10 weeks postinfection
(Figure 3, A and B), despite by that time a 10-fold reduction in
the number of granulomas (Figure 3C) and a 1000-fold
reduction in the number of BCG bacilli in infected tissue
(Figure 3D). By 10 weeks postinfection, there was a sevenfold
total increase in LYVE1þ area in infected liver compared to
uninfected mice. Though chronic granulomas contain 100 to
1000 fewer bacteria than acute granulomas, increased lym-
phatics could facilitate access of granuloma-containing anti-
gens to secondary lymphoid organs.
One important observation from these studies is the
heterogeneity of lymph distribution and proximity to
different granuloma subsets depending on their proximityThe American Journal of Pathology - ajp.amjpathol.orgto portal triads. Every granuloma adjacent to or inﬁltrated
by LYVE-1þ endothelium was also adjacent to a portal
triad. Additionally, all areas that had increased lymphatic
area compared to uninfected controls were directly adja-
cent to granulomatous inﬂammation. These ﬁndings
suggest that the association between granulomatous
inﬂammation and lymphangiogenesis likely stems from
the anatomic location of granuloma formation, and its
proximity to pre-existing lymphatic structures. Our data
show that despite signiﬁcant resolution of inﬂammation
and reduction in bacterial burden, the few granulomas that
persist near portal triads during chronic infection continue
to induce lymphangiogenesis. Based on the variable dis-
tribution of distance between granulomas and lymphatics,
it is also likely that different granulomas have different
lymphatic access.
Lymphangiogenesis Is Regulated by Vegfr3 during BCG
Infection
Next, we investigated the molecular regulators of lym-
phangiogenesis during mycobacterial infection. It has been437
Figure 5 Mycobacterial-speciﬁc T-cell activation decreases with
blockade of lymphangiogenesis. Bacillus Calmette-Guerin (BCG)einfected
mice were treated with MAZ51 (Vegfr3 inhibitor) for 7 days before harvest
at 21 days post infection. On the ﬁrst day of MAZ51 treatment, mice
received CFSE-labeled mycobacterial-speciﬁc P25 T cells. A: Representative
ﬂow plot from mice shows identiﬁcation of transferred P25 T cells in spleen
and liver draining lymph nodes (top panels), as well as CFSE dilution
(bottom panels, from gate shown in A). B: Quantiﬁcation of data from A.
t-Test used to determine statistical signiﬁcance. Data are expressed as
means  SEM (B). n Z 3 to 5 (B, mice per group). *P < 0.05.
Harding et alpreviously reported that lymphangiogenesis is strongly
regulated by Vegfr3 binding to Vegf-c.6e9 We measured
Vegf-c concentration in cell culture supernatant of splenic
and granuloma-isolated leukocytes 3 weeks after i.p.
infection with BCG. Vegf-c from splenic leukocytes of
uninfected mice fell below the detection limit of the ELISA
(Figure 4A). Vegf-c was detected in supernatants from
cultured leukocytes from the liver and spleen of BCG-
infected mice, but at threefold higher concentrations in
liver granuloma supernatants (Figure 4A). We then treated
BCG-infected mice with the small molecule VEGFR3
inhibitor MAZ51 (a receptor tyrosine kinase inhibitor50) at
10 mg/kg per day for 7 days leading up to acute infection.
The expected increase in LYVE-1þ staining after BCG
infectionwas signiﬁcantly mitigated whenmice were treated
with MAZ51 prior to harvest (Figure 4, B and C). Reduced
lymphangiogenesis inMAZ51-treatedmice did not correlate
with or result from changes in the overall inﬂammatory
response in the liver. A week of lymphangiogenesis-
blocking treatment with MAZ51 treatment did not lead to
granulomatous inﬂammation with fewer CD11bþ cells
(Figure 4, DeF) total CD11bþ cells (Figure 4F), or total
number of granulomas (Figure 4G). These data show
that VEGF-C is up-regulated in granulomatous tissue,
and that lymphangiogenesis during acute mycobacterial
infection can be blocked via inhibition of Vegfr3.
Together, these data are consistent with reports showing
Vegfr3 as the primary regulator of lymphangiogenesis
during inﬂammation.6,12,13
Lymphangiogenesis Regulates BCG-Speciﬁc T-Cell
Proliferation
Lymph vessels have traditionally been characterized as
conduits that drain lymph ﬂuid from the tissue and, during
infection, facilitate emigration of antigen to the lymph
nodes (with or without antigen-presenting cells) for
adaptive immune priming. Only recently have changes in
the phenotype of lymph endothelial cells themselves been
shown to functionally regulate immunity during inﬂam-
mation and infection. Furthermore, although lymphangio-
genesis has been described during many inﬂammatory
states, the functional consequences of lymph vessel growth
on immunity are poorly understood. We asked whether the
measured increase in lymphangiogenesis during acute
mycobacterial infection had a role in the resulting adaptive
immune response.
We treated BCG-infected mice with MAZ51 for 7 days
before harvest at 21 days postinfection. On the day of
treatment, mice received an intravenous injection of
1  106 CFSE-labeled P25 T cells, which recognize a
peptide from the mycobacterial-secreted antigen 85b. P25
cells express endogenous DsRed ﬂuorescent protein,
which allows in vivo tracking and isolation by ﬂow
cytometry. These transgenic T cells undergo robust pro-
liferation and activation during mycobacterial infection438when they recognize 85b peptide after circulation into the
lymph nodes via lymphatics. P25 T cells were isolated
from the spleens and liver-draining lymph nodes of
MAZ51-treated mice during acute BCG infection
(Figure 5, A and B). The frequency of P25 T cells in
proliferation was 50% lower in the spleen, and 25% lower
in the liver-draining lymph nodes in MAZ51-treated mice,
compared to vehicle-treated controls. In both the spleen
and lymph node, reduced proliferation correlated with a
nearly 50% reduction in the frequency of P25 T cells.
These results suggest that additional lymphatic vessels
may increase the access of granuloma antigens to periph-
eral immune sites and facilitate or progress the initiation of
adaptive immune responses.
Lymphangiogenesis Is Induced in the Lung after MTB
Infection and Regulates MTB-Speciﬁc T-Cell
Proliferation
Our previous studies focused on granuloma-induced lym-
phangiogenesis in the liver using a systemic BCG infection
model. We next asked whether lymphangiogenesis is
induced in the lungs by granulomatous inﬂammation after
localized infection with MTB, if it is regulated by Vegfr3,
and whether it regulates mycobacterial-speciﬁc T cells.
Wild-type C57BL/6 mice were aerosol infected with H37Rv
MTB and harvested 28 days later, by which time acute
infection and granuloma formation follows extensive
leukocyte inﬁltration into the lungs (Figure 6A). MTB lungajp.amjpathol.org - The American Journal of Pathology
Figure 6 Mycobacterium tuberculosis (MTB)-induced lymphangiogenesis in the lung. MTB infection results in murine lung lymphangiogenesis, and blockade
of Vegfr3 reduces mycobacterial-speciﬁc T-cell proliferation. A: Sixty micrometer thick sections from the left lung of uninfected and MTB-infected mice shows
CD11bþ granulomatous inﬂammation and increased LYVE1þ area that results 4 weeks after aerosol infection with MTB. B: Quantiﬁcation of increased lymph
endothelium, measured by LYVE-1, from image shown in A. C: Vegf-c concentration from cell culture supernatants of isolated lung and splenic leukocytes
(1  106 cells cultured for 24 hours). Leukocytes were isolated 6 weeks after aerosol infection with MTB. Vegf-c concentration from splenic leukocytes was
below the detection limit of the ELISA. D: Representative area of uninfected and MTB-infected lung showing LYVE-1þ vessels. Dashed lines show CD11b
cellecontaining granulomas. E: Higher magniﬁcation shows proximity of LYVE-1 staining with CD11bþ cells, some of which contain tdTomato-expressing MTB
bacilli (white arrows in top panel; bacilli can be distinguished by rod-like morphology). CD11bþ ﬂuorescent cells can be found inside the lumen of lymphatic
vessels (bottom two rows, orange arrows). F: Mycobacterial-speciﬁc, DsRed P25 T cells were transferred into MTB-infected mice that were treated with the
VEGFR3 blocker MAZ51 for 10 days. Frequency of P25 T cells in proliferation (measured by CFSE dilution), as well as the frequency of P25 T cells of total
leukocytes, was measured in the lung, spleen, and lung-draining lymph nodes. Representative ﬂow cytometry plots show CFSE dilution of P25 T cells. t-Test was
used to determine statistical signiﬁcance. G: Cells from the draining lymph nodes of Bacillus Calmette-Guerineinfected mice were co-cultured with CFSE-
labeled P25 T cells and 1 mg/mL puriﬁed mycobacterial 85b protein, along with 5 mg/mL MAZ51 (in 0.2% dimethyl sulfoxide). The proliferation of P25
cells was measured 3 days later. Data are expressed as means  SEM (B, C, and F). nZ 4 to 5 (B and C, animals per group); nZ 3 (G, animals per group).
*P < 0.05, **P < 0.01. Original magniﬁcation: 40 (A, 60-mm tissue cuts); 100 (D). LN, lymph node.
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Figure 7 Obstructed lymphatics observed in a subset of granulomas. A:
H&E staining of Mycobacterium tuberculosis (MTB)-infected lung (granulomas
outlined in black dashed lines), which show phenotypically different granu-
lomas in the same infected host. Non-obstructed lymphatics (area 1) and
obstructed lymphatics (area 2) were further analyzed in panels B and C
respectively. B and C: Fluorescent micrographs showing the differential
expression of LYVE-1þ staining depending on the size and density of the
granuloma. Granulomas are outlined in white dashed lines, and right panels
in B and C show magniﬁcations of areas indicated by white arrowheads
(B, non-obstructed lymphatics), andwhite arrows (C, obstructed lymphatics).
Most granulomatous inﬂammation is associated directly with or in proximity to
LYVE-1þ vessels (B), but a few large granulomas (C) have little or no proximity
to LYVE-1þ cells. No lymphatic obstruction is apparent in smaller granulomas,
and lymphatic vessels are not plugged with cells (yellow arrowhead). Certain
large lesions induce lymphatic obstruction, and LYVE-1þ cells are plugged with
granuloma cells (orange arrowhead) and/or have low LYVE-1 staining
intensity with perforated-like morphology (green arrowhead).
Harding et algranulomas are larger and contain more leukocytes, as well
as more MTB bacilli, than BCG liver granulomas. However,
both MTB and BCG granulomas contain similar proportions
of many cell types, including a dominant CD11bþ cell pop-
ulation. We measured lymphangiogenesis during acute pul-
monary MTB infection by quantifying the area enclosed by
LYVE-1þ vessels using tissue cuts (60 mm thick) of the entire
left lung. MTB-infected mice had an almost 50% increase in
the total area of lymphatic vessels compared to uninfected
controls (Figure 6, A and B). Under noninﬂammatory condi-
tions, the lung has a signiﬁcantly higher proportion of LYVE-
1þ area compared to the liver, which could explain why the
manigitude ofMTB-induced lymphangiogenesis in the lung is
smaller than that of BCG infection in the liver. Additionally,
VEGF-C was up-regulated in supernatants from lung-isolated
leukocytes ofMTB-infected mice, but was below the detection
limit of the ELISA from supernatants of cultured splenocytes
from the same mice (Figure 6C).
Most CD11bþ cellecontaining granulomas are found in
proximity to LYVE-1þ vessels (Figure 6D), and MTB bacilli
are found inside granuloma CD11bþ cells that make up the
granuloma (Figure 6E). We also found CD11bþ cells inside
the lumen of LYVE-1þ vessels (Figure 6E). Most CD11bþ
cells in mycobacterial granulomas are monocyte-derived
macrophages that phagocytose and eliminate bacteria. A
subset of CD11bþ cells are inﬂammatory DCs, which are
distinct from tissue resident DCs, but perform similar func-
tions in their ability to transport bacteria and bacterial pep-
tides to the lymph nodes. CD11bþ inﬂammatory DCs are
highly mobile and specialized in their ability to transmigrate
into the lymphatic lumen and emigrate to peripheral lymph
organs. CD11bþ macrophages have lower mobility by com-
parison and are retained in the granuloma; they are unlikely to
reside in the lumen of LYVE-1þ vessels.
We then tested the role of Vegfr3 on P25 T-cell prolif-
eration during pulmonary MTB infection. MTB-infected
mice were treated with MAZ51 10 days before harvest and
received 1  106 CFSE-labeled P25 T cells on the ﬁrst day
of treatment. Blockade of Vegfr3 resulted in 25% fewer
P25 T cells in proliferation in the lung-draining lymph
nodes and 50% fewer in the lung (Figure 6F). Reduced
proliferation correlated with fewer P25 T cells (Figure 6F,
upper right). One interesting observation was that P25
proliferation was inhibited by MAZ51 treatment when
BCG was given via i.p. injection, but not by aerosol
inhalation, which may be due to the fact that i.p. injection
induces systemic infection with high splenic CFU. Infec-
tion via inhalation results in a lung-localized infection,
with fewer bacilli in the spleen. In certain cancers, lym-
phangiogenesis can facilitate metastasis by increasing the
access of tumor cells to lymph vessels and other routes to
peripheral sites.51e53 We did not measure differences in
splenic bacterial burden of MAZ51-treated, MTB-infected
mice compared to vehicle-treated controls (data not
shown), which suggests that differences in P25 prolifera-
tion do not result from increased bacterial dissemination.440We also tested whether MAZ51 had a direct inhibitory effect
on P25 T cell proliferation. We co-cultured cells from the
draining lymph nodes of BCG-infected mice with CFSE-
labeled P25 T cells and added 5 mg/mL MAZ51, as well as 1
mg/mL puriﬁed mycobacterial 85b protein (Figure 6G). After 3
days in culture, the frequency of P25 T-cell proliferation from
cultures treated with MAZ51 was similar to that of vehicle-
treated ones, showing that the capacity of DCs to stimulate
P25 cells is not altered by the presence of MAZ51. Taken
together, these data show that MTB-induced granulomatous
inﬂammation induces local lymphangiogenesis and VEGF-C
in infected tissue, and that inhibition of Vegfr3 reduces
mycobacterial-speciﬁc T-cell responses. Together with pre-
vious experiments, these data show that the mechanisms of
induction, as well as functional consequences of lym-
phangiogenesis, are similar among different tissue-speciﬁc
models of granulomatous inﬂammation.
Obstructed Lymphatics Are Observed in a Subset of
Granulomas
In the lungs of MTB-infected mice, granulomas are
phenotypically different from one another, with variableajp.amjpathol.org - The American Journal of Pathology
Figure 8 Model of lymphangiogenesis and
lymphatic obstruction during granulomatous
inﬂammation. Mycobacterial-induced granulomas
around lymphatic vessels in infected tissues result
in Vegf-cemediated lymphangiogenesis via vessel-
expressed Vegfr3. Increased lymphatic endothe-
lium provides increased surface area for antigen
presenting cells from the granuloma to emigrate to
the lymph nodes with bacteria or bacterial antigens
and prime mycobacterium-speciﬁc T cells. After
adaptive immunity has been generated (indicated
by white dotted line), granulomatous inﬂamma-
tion can resolve, though certain granulomas may
continue to accumulate cells. These granulomas are
of a scale and density that can result in obstructed
lymphatics. Granulomas with this phenotype likely
result from sustained and increasing inﬂammation
that correlates with poor protection or deﬁcient
elimination of mycobacteria.
Mycobacteria and Lymphangiogenesissize, number of accumulated cells, and cell density
(Figure 7A). Most of the inﬂammatory foci in MTB-infected
lungs surround or have proximity to LYVE-1þ endothelium
(Figure 7B). However, we observed a subset of MTB granu-
lomas with little or no lymphatic endothelium inside or in
proximity to the site (Figure 7C). A deﬁning phenotype of
these granulomas is that they are larger than many MTB-
containing foci, and have higher cell density with tighter cell
aggregation. Lymphatics that are found in these granulomas
have reduced LYVE-1 expression and/or endothelium that
appears compromised and perforated (Figure 7C). The lumen
of lymph vessels found in large, tightly packed granulomas are
often completely obstructed and ﬁlled with granuloma cells
(Figure 7C). By comparison, lymph vessels were found in or
around smaller granulomas are clear and have no plugging of
the lumen with cells (Figure 7B).Discussion
The mechanisms and consequences of lymphangiogenesis
have received far less attention than angiogenesis, and most
studies are in the context of developmental lymphangio-
genesis. Only more recently has lymphangiogenesis, and itsThe American Journal of Pathology - ajp.amjpathol.orgmolecular mechanisms during inﬂammation, trans-
plantation, and disease been investigated. For example,
lymphangiogenesis occurs in the cornea alongside neo-
vascularization after the induction of inﬂammation and is
mediated by CD11bþ macrophages.13 Dramatic increases
are observed in lymphangiogenesis and hyperplasia in the
airway after infection with Mycoplasma pulmonis.12 Here,
we describe lymphangiogenesis during granulomatous
inﬂammation induced by mycobacterial species, including
BCG and MTB.
We have shown that CD11bþ cell-dominated granulo-
matous inﬂammation results in high levels of Vegf-c and
induces lymphangiogenesis. This ﬁts the knowledge that
macrophages are a source of Vegf-c and one of the most
important inducers of lymphangiogenesis. The molecular
inducers of VEGF-C remain incompletely understood,
though hypoxia, which induces VEGF-A and VEGF-B,
can induce VEGF-C in certain tumor cell lines via the
hypoxia-inducible factor (HIF)-1a transcription factor.54,55
It is not surprising that Vegf-c and lymphangiogenesis
might be coregulated by proangiogenic factors given that
angiogenesis is often a wound repair or injury respon-
sedthese states could also require increased lymph
drainage resulting from inﬂammation. Tumor necrosis441
Harding et alfactor (TNF)-a and IL-1b, two molecules secreted by
macrophages in mycobacterial granulomas,56e64 up-
regulate VEGF-C by increasing mRNA transcription.65
TNF-a induces VEGF-C in the synovial ﬂuid of patients
with rheumatoid arthritis,66 and TNF-a also correlates with
VEGF-C expression in lymphedema.67 A recently identi-
ﬁed VEGF-Ceinducing transcription factor, LEDGF/p75,
is itself regulated by reactive oxygen species,68 which are
critical mediators of the antimicrobial response in myco-
bacterial granulomas.69e71 VEGF-C has been induced in
human umbilical vein endothelial cells by sphingosine-
1-phosphate, but up-regulation is blocked by inhibition of
matrix metalloproteinase (MMP)-2.72 Multiple MMPs,
including MMP-2, are up-regulated in mycobacterial granu-
loma macrophages and thought to facilitate granuloma
expansion by degrading extracellular matrix.73e76 Together,
these studies show that multiple factors that are up-regulated
in granulomas can also induce VEGF-C expression.
One important observation from our studies is that the
relationship between increased lymphatics and granulomas is
heterogeneous. Access of the granuloma to lymph vessels
depends on where the granuloma forms in the tissue, as well
as the anatomy of the tissue itself. In the liver, new vessels are
likely sprouting from pre-existing vessels located in the portal
triad, suggesting that lymphangiogenesis may be induced
only by the subset of granulomas near portal triads. Bacteria-
containing cells near portal triads may therefore have
increased lymphatic access compared to more distal ones,
suggesting that the site of granuloma initiation dictates
its lymphatic access. In MTB-infected lung, the gran-
ulomaelymphatic relationship was also heterogeneous, but
for a different reason. In this context, lymphatic access was
also dependent on whether the granuloma induced lymphatic
obstruction. Patients with granulomatous diseases such as
Crohn disease have lymphangitis in the gut,77 alongside
extensive lymphatic remodeling.78e82 Granulomas in these
patients can obstruct lymphatics either by plugging the lumen
of the vessel or distorting the vessel from the outside. Our
study shows that lymphangiogenesis has a functional role in
inducing mycobacterial-speciﬁc T-cell responses, suggesting
that lymphatic obstruction could impair the generation of
adaptive immune response to granuloma pathogens. In our
studies, decreased T-cell proliferation after Vegfr3 inhibition
did not affect the bacterial burden in granulomatous or
splenic tissue, though mice were harvested at the peak of
acute infection. It is possible that the observed decrease in
T-cell proliferation alters the outcome of infection, but that it
occurs during the chronic and/or resolution stage of infection.
Moving forward, it will also be important to test the effects of
long-term Vegrf3 inhibition.
We propose a model in which granulomatous inﬂamma-
tion in proximity to existing lymphatic vessels induces lym-
phangiogenesis after monocyte-released Vegf-c binds to
vessel-expressed Vegfr3 (Figure 8). Lymphangiogenesis
facilitates increased CD11cþ emigration out of granulomas
associated with lymph vessels and into the lymph nodes442where they prime mycobacterial-speciﬁc T cells. The role of
lymph vessels and lymphangiogenesis on the immune system
to infection is rapidly expanding. These include direct mod-
ulation of both DC and T-cell interactions with lymphatic
endothelium. Some of these reports have uncovered molec-
ular mechanisms by which lymphatics down-regulate or tol-
erize T cells.14,16,83 Since lymph vessels serve as important
conduits by which emigrating DCs initiate adaptive immu-
nity, it is not surprising that they serve as points of regulation
in preventing autoimmunity or excessive inﬂammation during
infection. Our data show a T-celleactivating role of the
lymphatics during mycobacterial infection, though simulta-
neous and suppressive regulation may also be possible at the
individual lymphatic endotheliumeDC point of contact.
We also showed that lymphangiogenesis can occur despite
resolution of acute infection, which involves a 10-fold
reduction in granuloma burden and 1000-fold reduction in
bacterial load. This is consistent with the fact that remodeled
lymph vessels after mycoplasma infection remain 12 weeks
after antibiotic treatment; by contrast, remodeled blood ves-
sels resolved by 2 weeks post-treatment.12 Lymphangio-
genesis during chronic inﬂammation and infection remains
poorly understood. Unknown questions involve the length of
persistence of new lymph vessels, the fate of new vessels
after resolution of acute inﬂammation, and the functional
consequences for tissues that have been remodeled with
lymph vessels. Recently, DCs were shown to transport
mycobacterial antigen to the lymph and prime T cells during
the acute and chronic stages of infection.45 Our studies sug-
gest that continued lymphangiogenesis through chronic
infection could be beneﬁcial by facilitating this continuous
antigen sampling, as well as draining inﬂammation-related
ﬂuids, even at the lower antigen abundance present in
chronic conditions. On the other hand, dendritic emigration to
peripheral sites is known to facilitate mycobacterial dissem-
ination, and increases in lymphatic endothelium could exac-
erbate this problem.84 It will be important to understand the
relationship between the granuloma and lymphangiogenesis
given that many diseases, including tuberculosis, induce
chronic granulomatous inﬂammation. These include leprosy,
histoplasmosis, sarcoidosis, schistosomiasis, and Crohn
disease, to name a few.
In our studies, the same granulomatous inﬂammation that
induces lymphangiogenesis could also obstruct lymphatics if
the inﬂammation was of a certain scale and density. This
observation is ﬁtting with recent evidence that protection, or
loss of protection, is granuloma-speciﬁc and likely different
for every granuloma.85,86 In MTB-infected lung, whether an
individual granuloma induces lymphatic obstruction likely
relates to bacterial control and/or resolution of the site. Pro-
tection in the granuloma correlates with bacterial killing and
resolution, in which effector leukocytes are no longer repo-
pulated. Even chronic granulomas with a few persisting
bacteriadwhich require low-level cell recruitmentdstill
undergo signiﬁcant resolution after acute infection. Granu-
lomas that induce lymphatic obstruction are likely those withajp.amjpathol.org - The American Journal of Pathology
Mycobacteria and Lymphangiogenesisdeﬁcient bacterial killing, resulting in sustained and
increasing cell recruitment. Extensive and overwhelming
inﬂammation correlates with loss of protection and bacte-
rial expansion. The consequences of lymphatic obstruction
could be an important component of tuberculosis pathology
in patients with active or severe diseases. Obstruction of
lymph in the gut has long been hypothesized pathological
in Crohn and inﬂammatory bowel disease, where blockage
can result in poor ﬂuid drainage and edema. In mycobac-
terial granulomas, severe blockage could impair drainage
of antigen-presenting cells and reduce activation of
mycobacterial-speciﬁc T cells. In our studies, MTB granu-
lomas in the lung are heterogenous, with varying size and
bacterial load. Only a subset of granulomas in the lungs was
of the scale and size that seemed necessary to induce
lymphatic obstruction. This is ﬁtting with the ﬁndings that
protection, or loss of protection, is granuloma-speciﬁc. In
mice, low-dose aerosol infection with MTB does not result in
morbidity during acute infection, despite high bacterial
burden and high levels of inﬂammation in the lung. This
explains why, in our model, only a subset of granulomas have
the phenotype correlated with obstruction. It is likely that
these represent the subset found at a higher frequency in
moribund mice and humans.
Conclusion
Induced lymphangiogenesis is associated with granuloma
formation, and this process contributes to granuloma-driven
systemic immune responses. A better understanding of the
factors that regulate lymphangiogenesis, as well as the
relationship between lymphoid tissue and granulomas, will
improve our understanding of granulomatous diseases.
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